The Lewy Body Dementia drugs in development market research report provides comprehensive information on the therapeutics under development for Lewy Body Dementia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Lewy Body Dementia. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Lewy Body Dementia - Drugs In Development, 2023

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Lewy Body Dementia and features dormant and discontinued products.

GlobalData tracks 46 drugs in development for Lewy Body Dementia by 36 companies/universities/institutes. The top development phase for Lewy Body Dementia is preclinical with 21 drugs in that stage. The Lewy Body Dementia pipeline has 45 drugs in development by companies and one by universities/ institutes. Some of the companies in the Lewy Body Dementia pipeline products market are: Parkure, Cognition Therapeutics and AriBio.

The key targets in the Lewy Body Dementia pipeline products market include Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA), Tyrosine Protein Kinase ABL1 (Abelson Murine Leukemia Viral Oncogene Homolog 1 or Abelson Tyrosine Protein Kinase 1 or Proto Oncogene c Abl or p150 or ABL1 or EC 2.7.10.2), and Membrane Associated Progesterone Receptor Component 1 (Sigma 2 Receptor or PGRMC1).

The key mechanisms of action in the Lewy Body Dementia pipeline product include Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) Inhibitor with six drugs in Phase II. The Lewy Body Dementia pipeline products include four routes of administration with the top ROA being Oral and eight key molecule types in the Lewy Body Dementia pipeline products market including Small Molecule, and Monoclonal Antibody.

Lewy Body Dementia overview

Lewy body dementia (LBD) is a progressive neurodegenerative disorder characterized by the abnormal accumulation of alpha-synuclein protein deposits (Lewy bodies) in the brain. This condition shares similarities with both Alzheimer’s disease and Parkinson’s disease, presenting a complex spectrum of symptoms that affect cognition, movement, behavior, and autonomic functions. LBD manifests through various symptoms that may fluctuate in severity, including cognitive changes (impaired thinking, attention, and visual-spatial abilities); fluctuating attention and alertness; visual hallucinations, often detailed and recurrent; motor symptoms (Parkinsonism, such as stiffness, slowness, tremors, and gait disturbances); and sleep disturbances, including REM sleep behavior disorder (acting out dreams).

For a complete picture of Lewy Body Dementia’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.